RESUMO
PURPOSE: Abiraterone has been proven to be an effective agent used in the management of metastatic castration-resistant prostate cancer, significantly improving overall and progression-free survival. Due to the pharmacodynamic and pharmacokinetic properties of abiraterone, concurrent use with anticoagulation may pose a challenge for clinicians. Thrombosis within the cancer setting continues to increase patient mortality; therefore, appropriate anticoagulation through the use of a management algorithm can reduce adverse events and increase quality of life. METHODS: A review of the literature was preformed by a medical oncologist, haematologist and pharmacists to identify relevant randomized controlled trials, meta-analyses and retrospective studies. Major society guidelines were reviewed to further aid in developing the anticoagulation protocol for non-valvular atrial fibrillation and venous thromboembolism within this patient population. After reviewing the literature, a clinical framework was designed to aid clinicians in the management of those patients receiving abiraterone concurrently with an anticoagulant. RESULTS: In this review, we describe the potential interactions between abiraterone and various anticoagulants and provide management strategies based on the most recent literature for atrial fibrillation, venous thromboembolism and mechanical heart valves to avoid potential drug-drug interactions. CONCLUSION: Abiraterone therapy has become a mainstay of the management of advanced prostate cancer and is often used over prolonged years. In this review, we have summarized a framework of how to use abiraterone in men with prostate cancer on anticoagulants. Evidence available to date suggests that patients with an indication for anticoagulation such as atrial fibrillation, venous thromboembolism and mechanical heart valves can be treated safely with abiraterone in the appropriate setting, with appropriate monitoring.
Assuntos
Androstenos/efeitos adversos , Anticoagulantes/efeitos adversos , Anticoagulantes/uso terapêutico , Antineoplásicos/efeitos adversos , Interações Medicamentosas , Trombose/tratamento farmacológico , Trombose/prevenção & controle , Androstenos/uso terapêutico , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Progressão da Doença , Humanos , Masculino , Prednisona/uso terapêutico , Neoplasias de Próstata Resistentes à Castração/sangue , Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico , Neoplasias de Próstata Resistentes à Castração/patologia , Qualidade de Vida , Estudos Retrospectivos , Resultado do TratamentoAssuntos
Infecções Oportunistas Relacionadas com a AIDS/diagnóstico , Leishmaniose Visceral/diagnóstico , Anfotericina B/uso terapêutico , Anemia/etiologia , Animais , Contagem de Células Sanguíneas , Exame de Medula Óssea , Canadá , Diagnóstico Diferencial , Febre/etiologia , Guiana/etnologia , Infecções por HIV/complicações , Humanos , Leishmania/isolamento & purificação , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/etiologia , Masculino , Pessoa de Meia-Idade , Exame Físico , Esplenomegalia/etiologia , Trombocitopenia/etiologia , Tripanossomicidas/uso terapêuticoRESUMO
Venous thromboembolism (VTE) is a frequent but often silent complication of critical illness that has a negative impact on patient outcomes. The prevention of VTE is an essential component of patient care in the intensive care unit (ICU) setting, and is the focus of this article. The use of anticoagulant thromboprophylaxis significantly decreases the risk of VTE in ICU patients and is discussed at length.